Next, the enrolled participants were classified as ApoE ε4 carriers or ApoE ε4 noncarriers, and the results showed that there were more ApoEε4 carriers among AD and MCI patients than among HCs (P < 0.001, Table 1). This evidence concerns the gene APOE and Alzheimer disease.